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The HIV-1 envelope glycoprotein gp120 is the key determinant for the anti-HIV-1 entry activity of IC9564. AT198P mutation in the gp120
of the HIV-1 primary isolate, DH012, drastically increases IC9564 sensitivity, which can be reversed by growing the virus in the presence of
IC9564. The reversed resistant variants contain a P198S mutation that fully confers the drug-resistant phenotype. Although the amino acid
residue at position 198 of gp120 can alter IC9564 sensitivity, results from this study suggest that T198 is not the direct target of the compound.
The mutation at position 198 appears to affect the conformation of gp120 and subsequently decreases the accessibility of the drug target. This
conformational effect is evidenced by the fact that the T198P mutation significantly increases the neutralizing activity of the conformational
antibodies, 1b12 and 48d. On the other hand, the IC9564 escape variant with the P198S mutation is resistant to these conformational antibodies
and highly sensitive to the potent neutralizing antiserum, C1206, which recognizes a conformational epitope involving the sequences from V1,
V2, and V3 regions in gp120. Thus, results from this study indicate that the conformation of gp120 can be exploited by HIV-1 to escape IC9564.
D 2004 Elsevier Inc. All rights reserved.Keywords: HIV-1 envelope glycoprotein; HIV-1 DH012; IC9564
Introduction that can inhibit both R5 and X4 HIV-1 strains (Holz-SmithBetulinic acid derivatives are a class of small molecules
that can potently inhibit HIV-1 replication (Hashimoto et al.,
1997; Holz-Smith et al., 2001; Huang and Chen, 2002;
Mayaux et al., 1994; Soler et al., 1996; Sun et al., 2002). In
general, these molecules contain a five-membered ring
scaffold and a functional side chain. Depending on the
position of the functional side chain, the targets of betulinic
acid derivatives are varied. For example, dimethylsuccinyl
betulinic acid, with a functional side chain at position 3,
inhibits HIV-1 maturation (Hashimoto et al., 1997; Kana-
moto et al., 2001; Li et al., 2003; Zhou et al., 2004). On the
other hand, 28-betulinylaminooctanoylamino-3R-hydroxy-
6-methylhextanoic acid (IC9564) and its analogs with a
side chain at position 28 are potent HIV-1 entry inhibitors0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2004.04.009
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E-mail address: chc@duke.edu (C.H. Chen).et al., 2001; Sun et al., 2002).
In an effort to study the mechanism of action, we have
identified mutations in gp120 that are responsible for
resistance to IC9564 (Holz-Smith et al., 2001). There are
no gp41 mutations that significantly affect the anti-HIV
activity of IC9564. The mutations in gp120 are dispersed in
regions of gp120 where their functions are not well charac-
terized. Thus, the mechanism of drug resistance and the
direct target of IC9564 remain unclear. In contrast, the
determinant of the anti-HIV-1 entry activity of
RPR103611 was initially mapped to gp41 (Labrosse et al.,
1997). IC9564 and RPR103611 are stereoisomers and
appear to be equally potent in their anti-HIV-1 activity.
However, it was later suggested that the key determinant for
RPR103611 is the affinity between gp41 and gp120 (Lab-
rosse et al., 2000). These discrepancies do not rule out the
possibility that IC9564 and RPR103611 share the same
mechanism of action. For example, it has been reported
that an escape mutant resistant to a gp120 specific neutral-
izing monoclonal antibody was associated with a single
amino acid mutation in gp41 (Reitz et al., 1988). It is
Fig. 2. gp120 sequence of NL4-3, DH012, and DH012 mutants. NLDH120
and M2-NLDH are HIV-1 strains containing DH012 wild-type gp120 and
T198P mutation, respectively. M2-NLDH-ICR is an IC9564-resistant virus
X. Yuan et al. / Virology 324 (2004) 525–530526possible that the mutations in gp120 could affect the affinity
between gp120 and gp41.
The objective of this study is to determine how HIV-1
escapes the anti-HIV-1 entry activity of IC9564. Our results
suggest that the bridging sheet of gp120 is a key determi-
nant in IC9564 sensitivity. A single amino acid change,
T198P, on the V1/V2 stem of gp120 is sufficient to alter the
sensitivity of DH012 to IC9564. However, the results
suggest that T198 is not the direct target of IC9564. The
mutation at position 198 alters the drug sensitivity of
DH012 by changing the accessibility of the IC9564 target.
Indeed, changing the target accessibility appears to be the
dominant viral strategy for resistance to IC9564 that targets
functionally critical sites on gp120.developed by growing M2-NLDH in the presence of escalating concen-
trations of IC9564. P/S-M2-pSW120 and V/I-M2-pSW120 are site-directed-
mutagenesis mutants carrying the P198S mutation and V37I mutation in
DH012 gp120, respectively. These mutations were introduced using a
Strategene quick exchange mutagenesis kit (Holz-Smith et al., 2001).Results and discussion
Inhibition of CD4-independent virus infection
To determine the effect of IC9564 on CD4/gp120 inter-
action, we tested the activity of IC9564 against the replica-
tion of a CD4-independent virus strain 8x (Hoffman et al.,
1999). IC9564 can potently inhibit the replication of HIV-1
8x in CD4 negative BC7 cells (Fig. 1). On the other hand,
DH012 is one of the CD4-dependent viruses that are
relatively resistant to IC9564. The inhibition of 8x infection
strongly suggests that the target of IC9564 is at a step after
the gp120/CD4 interaction. The binding of gp120 to CD4
and subsequent interaction with chemokine receptors are
critical fusion events in HIV-1 fusion and entry. Thus, it is
possible that the chemokine receptor interactive site of
gp120 is the key determinant for the anti-fusion activity of
IC9564.Fig. 1. IC9564 inhibits CD4-independent virus replication. HIV-1 8x and
DH012 were tested in a virus replication assay using BC7 cells and CEM
cells, respectively. The control samples contain an average of 25 ng/ml of
p24. The % control was determined as the ratio of p24 amount produced in
the presence of IC9564 over the amount of p24 in the control samples
multiplied by a factor of 100. Each data point represents the mean F SD of
two independent duplicated experiments.The bridging sheet region of gp120 is a key determinant for
IC9564 anti-entry activity
To determine the role of the bridging sheet of gp120 in
IC9564 sensitivity, we compared the replication of a pair of
HIV-1 strains, NLDH120 and M2-NLDH, in the presence of
IC9564. These two viruses exhibit significant differences in
the accessibility of the chemokine receptor interactive sites
(Zhu et al., 2001). Chemokine receptor binding site is
implicated to contain residues near or within the bridging
sheet and V3 loop (Rizzuto et al., 1998). NLDH120 and
M2-NLDH differ by one amino acid at position 198 in theFig. 3. A bridging sheet mutation increases IC9564 sensitivity. A MAGI
assay was used to determine the sensitivity of NLDH120, M2-NLDH, and
N197K-NLDH120 to IC9564. The infected cells were stained blue at the
end of the assay. The number of blue cells was enumerated by using an
imager from Southern Micro Instruments (Atlanta, GA). The control
infections were performed by infecting the MAGI cells with the viruses in
the absence of IC9564. A typical control infection yields approximately 400
blue cells. Each data point represents the mean F SD of two independent
duplicated experiments.
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NLDH, with a Threonine to Proline mutation at position 198
(T198P), is more sensitive to monoclonal antibodies, such
as 17b, with epitopes that overlap chemokine receptor
binding site (Zhu et al., 2001). Fig. 3 shows that M2-NLDH
is at least a log more sensitive to IC9564 than NLDH120,
which contains wild-type DH012 gp120 (Zhu et al., 2001).
An N197K mutation resulted in a variant that exhibited an
intermediate IC9564 sensitivity. Because both T198P and
N197K eliminate the glycosylation site at residue 197, the
sugar moiety on N197 is unlikely the target of IC9564. One
possible interpretation of the result is that T198 in the
bridging sheet region of gp120 is the direct target of
IC9564. However, HIV-1 NL4-3, which possesses the same
T198 and flanking amino acids as NLDH120, is as sensitive
to IC9564 as M2-NLDH (Holz-Smith et al., 2001). This
suggests that T198 is not the direct binding site for IC9564.Fig. 4. P198S mutation reverses drug-resistant phenotype. (a) Each of the two mu
M2-pSW120 (Zhu et al., 2001). The resulting envelope mutants, P/S-M2-pSW12
described (Holz-Smith et al., 2001). MAGI cells were used as the fusion partners
fusion were stained blue and enumerated as previously described (Holz-Smith et a
M2-pSW120 in the absence of the inhibitor yields approximately 100 syncytia in a
SD of two independent duplicated experiments. (b) Fluorescence activated cell
expressed on COS cells under the same conditions described in (a). The monoclo
sorter (FACS) analysis.Like M2-NLDH, viruses with a mutation in N197 become
more sensitive to neutralizing antibodies presumably due to
an altered envelope conformation that is relatively accessi-
ble to antibodies (Kolchinsky et al., 2001). Perhaps
NLDH120 envelope assumes a conformation that renders
the target of IC9564 less accessible. If this is indeed the
case, a phenotype revertant with an envelope conformation
resembling that of NLDH120 might emerge from M2-
NLDH in the presence of IC9564.
Conformation of DH012 gp120 determines IC9564
sensitivity
IC9564 escape mutants were selected by growing M2-
NLDH in the presence of IC9564 using a strategy previ-
ously described (Holz-Smith et al., 2001). The gp120 gene
sequence of the drug-resistant mutant, M2-NLDH-ICR, wastations, P198S or V37I, was introduced into the envelope expression vector
0 and V/I-M2-pSW120, were used in a modified fusion assay previously
for the envelope expressing COS cells. Syncytia derived from the cell –cell
l., 2001; Zhu et al., 2001). For example, a control fusion mediated by P/S-
well of a 96-well plate. Each data point in the figure represents the mean F
sorter analysis of envelope expression. The envelope glycoproteins were
nal antibody 1b12 at 10 Ag/ml was used in the fluorescence activated cell
Fig. 5. The P198S mutation renders M2-NLDH envelope less accessible to
neutralizing antibodies. The fusion assay described under Fig. 4 was used to
determine the effect of the P198S mutation on the neutralizing activity of
(a) the monoclonal antibodies 1b12 (solid lines) and 48d (dashed line) and
(b) C1206.
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Fig. 2. One mutation is a Valine to Isoleucine change at
position 37 (V37I). The other mutation is a Proline to Serine
change at position 198 (P198S), which is the key amino acid
that determines the differential IC9564 sensitivity of
NLDH120 and M2-NLDH. Each mutation was introduced
into M2-pSW120, which contains M2-NLDH envelope
sequence in the expression vector pSRHS (Holz-Smith et
al., 2001), and tested in an envelope-mediated fusion assay
(Holz-Smith et al., 2001). The V37I mutation does not
significantly affect the sensitivity of M2-pSW120 to
IC9564 (Fig. 4a). In contrast, introduction of the P198S
mutation into M2-pSW120 resulted in a mutant envelope P/
S-M2-pSW120 approximately 10-fold less sensitive to
IC9564 (Fig. 4a). Furthermore, the biochemical properties
of Serine are similar to that of Threonine in the wild-type
NLDH120 envelope. Thus, it is likely that the P198S
mutation might reverse the M2-NLDH envelope to a con-
formation similar to that of wild-type NLDH120. The
difference in IC9564 sensitivity could be due to an altered
expression level of the envelopes on cell surface. However,
there is no significant difference in binding of the mono-
clonal antibody 1b12 to gp120 of the wild-type and mutant
envelopes (Fig. 4b). Thus, the expression level of envelopes
is not responsible for the differential IC9564 sensitivity.
The envelope of P198S mutant is less accessible to
neutralizing antibodies
The effect of P198S mutation on neutralizing activity of
1b12 and 48d was evaluated in a fusion assay (Holz-Smith et
al., 2001). These two antibodies, 1b12 and 48d, interact with
CD4 binding site and CD4-induced epitopes on gp120,
respectively. The P/S-M2-NLDH envelope-mediated cell–
cell fusion is approximately 10-fold more resistant to 1b12
than M2-NLDH envelope (Fig. 5a). P/S-M2-NLDH enve-
lope-induced fusion is not inhibited by 48d presumably due
to inaccessibility of this CD4-induced epitope to the anti-
body. On the contrary, M2-NLDH envelope-mediated cell–
cell fusion can be inhibited by 48d (Fig. 5a). The resistance
of P/S-M2-NLDH to these antibodies suggests that the
P198S mutation reverse the envelope conformation to one
similar to that of wild-type DH012. DH012 envelope pos-
sesses a Threonine residue at position 198 and is relatively
resistant to neutralizing monoclonal antibodies (Zhu et al.,
2001). We have proposed that there is a physical interaction
between V1/V2 and V3 regions of gp120. As a result of this
interaction, the variable regions fold in such a way that the
binding sites of these neutralizing antibodies are concealed.
A potent neutralizing antiserum, C1206 (Cho et al.,
2000; Zhu et al., 2003), was used to provide additional
evidence that the P/S mutation indeed reverses the envelope
to a conformation similar to that of wild-type DH012. The
neutralization determinant of DH012 has been mapped to a
conformational epitope involving sequences from V1/V2,
V3, and V4. The T198P mutation disrupts the C1206epitope. As a result, M2-NLDH is resistant to C1206. A
fusion assay was used to determine the effect of the P198S
mutation on C1206 sensitivity (Fig. 5b). In agreement with
our earlier report, M2-pSW120-mediated membrane fusion
is resistant to C1206. In contrast, the envelope-mediated
syncytia formation by P/S-M2-pSW120 is highly sensitive
to C1206. These results further support the notion that
P198S mutation reverses the envelope to a conformation
similar to that of wild-type DH012.
It is well documented that the envelope of HIV-1 primary
isolates, such as DH012, is folded into a conformation that
conceals most of the critical structural motifs needed for
entry to avoid antibody neutralization (Moore et al., 2001;
Parren et al., 1999; Poignard et al., 2001; Zhu et al., 2001).
The results from this study suggest that DH012 can use the
same strategy in which gp120 folds into a conformation less
accessible to the inhibitor. Although the direct interactive
site of IC9564 remains to be determined, the amino acid
residues near or within the chemokine receptor interactive
site of gp120 are likely candidates. This conclusion is
supported by several observations. First, gp120 is the key
determinant for HIV sensitivity to IC9564. Second, IC9564
can potently inhibit a CD4-independent virus, 8x, replica-
tion in CD4 negative cells. Thus, the anti-HIV-1 entry
activity of IC9564 is likely due to its ability to interfere
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not interfere with chemokine-induced calcium flux (data not
shown), which suggests that IC9564 is not a chemokine
receptor antagonist. Lastly, mutations in the bridging sheet,
T198P and P198S, greatly affect IC9564 sensitivity of the
viruses. This suggests that the bridging sheet, a critical
gp120 motif involved in HIV-1 entry (Kwong et al., 1998;
Rizzuto et al., 1998), might be directly or indirectly in-
volved in the drug sensitivity.
Emergence of drug-resistant variants is inevitable for
almost all anti-HIV agents. HIV could use two mechanisms
to escape IC9564: (1) HIV-1 can alter the sequence of the
drug target. (2) The virus can change the conformation of
gp120 to decrease the accessibility of IC9564 binding site.
The IC9564-resistant variants derived from NL4-3 (Holz-
Smith et al., 2001) and M2-NLDH appeared to adapt the
later mechanism. It is possible that IC9564 targets a highly
conserved sequence that is essential for HIV-1 entry. As a
result, altering the accessibility of drug target becomes the
dominant strategy for HIV-1 to escape IC9564.Materials and methods
MAGI assay
Hela-CD4/CCR5/h-gal cells were plated on 48-well
tissue culture plates at 10,000 cells/well and cultured in
DMEM supplemented with 500 Ag/ml of G418 and 250 Ag/
ml of hygromycin B for 1 day. The cells were infected with
HIV-1 in the presence of neutralizing antibodies or entry
inhibitors then incubated at 37jC for 2 days. The cells were
fixed with a solution containing 1% formaldehyde and 0.2%
glutaraldehyde in phosphate-buffered saline. The infected
cells were then stained blue by adding X-gal (0.4 mg/ml) to
the cell culture. The number of infected cells was counted
by using an automated imager (Southern Micro Instru-
ments). A sample that inhibits 50% of virus infection is
defined by its ability to reduce the number of infected cells
by 50% (Chackerian et al., 1997; Zhu et al., 2001).
Cell fusion assay
The fusion assays were performed by transfecting COS
cells, a monkey kidney cell line, with the expression vector
pSRHS that contains the HIV-1 envelope genes. Electro-
poration was performed to express the HIV-1 envelope on
COS cells. Briefly, COS cells (106) in culture medium were
incubated with the envelope expression vector on ice for 10
min. The electroporation was performed using a gene pulser
(Bio-Rad, Hercules, CA) with capacitance set at 950 AF and
voltage at 150 V. The transfected COS cells were cultured
for 1 day and then mixed with the fusion partner, MAGI
cells. The MAGI cells (20  104) were incubated with the
envelope-expressing cells (2  104) in 96-well flat-bot-
tomed plates (Costar) in 100 Al of culture medium. Com-pounds at various concentrations in 10 Al of culture medium
were added to the cell mixtures. The cell/compound mix-
tures were incubated at 37jC for 24 h. Multinucleated
syncytia were stained blue and enumerated with an imager
designed and installed by Southern Micro Instruments.
Anti-HIV assay
A modified HIV-1 infectivity assay described previously
was used in the experiments (Zhu et al., 2001). A diluted
HIV-1 stock at a multiplicity of infection (MOI) of 0.001
TCID50/cell was used to infect cells. Twenty microliters of
the virus was incubated with 20 Al of compounds in RPMI
1640 containing 10% fetal bovine serum in a 96-well
microtiter plate. Twenty microliters of BC7 or CEM cells
at 6  105 cells/ml was added to each well, and the cell
culture was incubated at 37jC in a humidified CO2 incu-
bator. Two days after infection, fresh media (180 Al) con-
taining appropriate concentrations of the compounds were
added to each well. On day 4 post-infection, supernatant
samples were harvested and assayed for p24 using an
ELISA kit from ZeptoMetrix Corporation, Buffalo, NY.
FACS assay
The protocol for the FACS analysis was described
previously (Chen et al., 1995). HIV-1 envelope gene-trans-
fected COS cells were incubated with the monoclonal
antibody 1b12 at 4jC for 30 min on an orbital shaker.
The antibody was removed by washing the cells three times
with phosphate-buffered saline containing 1% fetal calf
serum (PBS-f). A fluorescence labeled secondary antibody
in PBS-f was added to the cells and incubated at 4jC for 30
min. The cells were washed three times with PBS-f before
resuspending in PBS plus 1% formaldehyde. The cells were
stored at 4jC until FACS analysis.Acknowledgment
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